GlassScriptPhysician profile
Ashley Coreth
NPI 1518579465
$2,946.84
in general payments reported to CMS, 2019-2025
24 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,034 · 2023: $1,057 · 2024: $534 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $280.40 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $255.98 | 2023-2025 | |
| Amgen INC. | $198.70 | 2022-2023 | Repatha |
| Merck Sharp & Dohme LLC | $198.22 | 2022-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.93 | 2022-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $166.91 | 2022-2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $162.74 | 2022-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $158.36 | 2022-2023 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $150.84 | 2022-2024 | Xarelto |
| Cardiva Medical, INC. | $149.13 | 2024-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
| Biotronik INC. | $119.26 | 2022 | |
| Shockwave Medical, INC | $118.75 | 2024-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Amarin Pharma, INC. | $113.89 | 2022-2023 | |
| Medtronic, INC. | $87.79 | 2023-2025 | Symplicity G3, Axium Primetm, Onyx Frontier |
| Esperion Therapeutics, INC. | $87.27 | 2022-2023 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $84.99 | 2023-2024 | Opticross 35 |
| Lexicon Pharmaceuticals, INC. | $70.00 | 2023-2024 | Inpefa |
| Abiomed | $65.70 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $58.63 | 2023-2024 | Sapien 3 Ultra Resilia |
| Kiniksa Pharmaceuticals, LTD. | $57.85 | 2022 | |
| Abbott Laboratories | $50.88 | 2024 | Diamondback Coronary, Coroflow |
| Medline Industries LP | $45.76 | 2024 | |
| Baxter Healthcare | $38.06 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Atricure, INC. | $37.80 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Coreth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.